Antibody-drug conjugates (ADCs) have emerged as one of the most promising modalities in oncology, offering a way to pair the targeting precision of antibodies with the potency of small-molecule drugs.
Conjugated antibodies are used in different clinical and non-clinical approaches. For example, antibody-drug conjugates (ADCs) and radioimmunoconjugates (RICs) may be used in the clinic for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results